Evidence map›Paper›PMID 25294123›Full record

ReviewBlood reviews2015

The development of potential antibody-based therapies for myeloma.

Daniel W Sherbenou, Christopher R Behrens, Yang Su, Jeffrey L Wolf, Thomas G Martin, Bin Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Anti-BCMA novel therapies for multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.International journal of molecular sciences · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Targeted Therapies in Adult B-Cell Malignancies.BioMed research international · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel W SherbenouDepartment of Medicine, University of California San Francisco, San Francisco, CA 94110, USA; Department of UCSF Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94110, USA.
Christopher R BehrensDepartment of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA.
Yang SuDepartment of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA.
Jeffrey L WolfDepartment of Medicine, University of California San Francisco, San Francisco, CA 94110, USA; Department of UCSF Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94110, USA.
Thomas G MartinDepartment of Medicine, University of California San Francisco, San Francisco, CA 94110, USA; Department of UCSF Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94110, USA.
Bin LiuDepartment of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA; Department of UCSF Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94110, USA.

Funding

Mapping a clinically significant internalizing tumor epitope space.R01CA118919 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2006 to 2013
$2.5M
Internalizing human antibody-targeted nanosized siRNA therapeuticsR01CA171315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2012 to 2016
$1.6M
Identifying antigens bound by novel scFvs targeting all subtypes of mesotheliomaR01CA129491 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2010 to 2013
$1.2M
NCI NIH HHS R01 CA118919NCI NIH HHS R01 CA129491NCI NIH HHS R01 CA 171315NCI NIH HHS R01 CA171315
6 · The paper itself

Abstract

With optimal target antigen selection antibody-based therapeutics can be very effective agents for hematologic malignancies, but none have yet been approved for myeloma. Rituximab and brentuximab vedotin are examples of success for the naked antibody and antibody-drug conjugate classes, respectively. Plasma cell myeloma is an attractive disease for antibody-based targeting due to target cell accessibility and the complementary mechanism of action with approved therapies. Initial antibodies tested in myeloma were disappointing. However, recent results from targeting well-characterized antigens have been more encouraging. In particular, the CD38 and CD138 targeted therapies are showing single-agent activity in early phase clinical trials. Here we will review the development pipeline for naked antibodies and antibody-drug conjugates for myeloma. There is clear clinical need for new treatments, as myeloma inevitably becomes refractory to standard agents. The full impact is yet to be established, but we are optimistic that the first FDA-approved antibody therapeutic(s) for this disease will emerge in the near future.

Indexed as

AnimalsAntibodies, MonoclonalHumansImmunoconjugatesImmunotherapyMultiple MyelomaAntibodies, MonoclonalImmunoconjugatesAntibody–drug conjugateImmunotherapyMonoclonal antibodiesMultiple myelomaPlasma cell myelomaTargeted cancer therapy

Identifiers

PMID25294123
PMCPMC4482758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.